The stock of TrovaGene Inc (NASDAQ:TROV) is a huge mover today! The stock increased 3.33% or $0.1 during the last trading session, hitting $3.1. About 81,108 shares traded hands. TrovaGene Inc (NASDAQ:TROV) has declined 51.69% since April 22, 2016 and is downtrending. It has underperformed by 57.10% the S&P500.
The move comes after 7 months positive chart setup for the $94.91 million company. It was reported on Nov, 25 by Barchart.com. We have $3.29 PT which if reached, will make NASDAQ:TROV worth $5.69 million more.
Analysts await TrovaGene Inc (NASDAQ:TROV) to report earnings on March, 9. They expect $-0.32 EPS, down 18.52% or $0.05 from last year’s $-0.27 per share. After $-0.34 actual EPS reported by TrovaGene Inc for the previous quarter, Wall Street now forecasts -5.88% EPS growth.
TrovaGene Inc (NASDAQ:TROV) Ratings Coverage
Out of 5 analysts covering TrovaGene (NASDAQ:TROV), 0 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 0 are positive. TrovaGene has been the topic of 8 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The firm has “Sector Perform” rating given on Tuesday, April 26 by Leerink Swann. The firm has “Outperform” rating given on Friday, August 14 by Leerink Swann. Cantor Fitzgerald downgraded TrovaGene Inc (NASDAQ:TROV) on Monday, April 25 to “Hold” rating. Piper Jaffray downgraded TrovaGene Inc (NASDAQ:TROV) on Monday, April 25 to “Neutral” rating. The firm earned “Neutral” rating on Friday, March 11 by Janney Capital. The stock has “Market Perform” rating given by Avondale on Tuesday, March 29. The stock of TrovaGene Inc (NASDAQ:TROV) earned “Buy” rating by Cantor Fitzgerald on Tuesday, September 15.
According to Zacks Investment Research, “Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics’ patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism.”
Insitutional Activity: The institutional sentiment increased to 1.29 in Q2 2016. Its up 0.48, from 0.81 in 2016Q1. The ratio is positive, as 8 funds sold all TrovaGene Inc shares owned while 23 reduced positions. 14 funds bought stakes while 11 increased positions. They now own 9.19 million shares or 9.18% less from 10.12 million shares in 2016Q1.
Creative Planning, a Kansas-based fund reported 9,700 shares. Elkhorn Partnership holds 55,913 shares or 0.17% of its portfolio. Goldman Sachs Gru accumulated 0% or 193,454 shares. Ladenburg Thalmann Fincl last reported 0% of its portfolio in the stock. Deutsche Savings Bank Ag accumulated 11,661 shares or 0% of the stock. Barclays Public Ltd Co has 23 shares for 0% of their US portfolio. Credit Suisse Ag reported 23,999 shares or 0% of all its holdings. Financial Bank Of Montreal Can last reported 13,558 shares in the company. Moreover, Blackrock Institutional Comm Na has 0% invested in TrovaGene Inc (NASDAQ:TROV) for 657,331 shares. Lba Wealth Mngmt Ltd Company reported 5,000 shares or 0.01% of all its holdings. Gsa Cap Partners Llp holds 0% or 11,000 shares in its portfolio. Moreover, Wells Fargo And Mn has 0% invested in TrovaGene Inc (NASDAQ:TROV) for 18,965 shares. Tci Wealth last reported 0.01% of its portfolio in the stock. State Street Corporation, a Massachusetts-based fund reported 389,653 shares. Amer Intl Grp Inc has invested 0% of its portfolio in TrovaGene Inc (NASDAQ:TROV).
More important recent TrovaGene Inc (NASDAQ:TROV) news were published by: Prnewswire.com which released: “Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments” on November 09, 2016, also Zacks.com published article titled: “Why Is Trovagene Inc. (TROV) Stock Soaring Today?”, Prnewswire.com published: “Trovagene Schedules Release of Second Quarter 2016 Financial Results and …” on July 26, 2016. More interesting news about TrovaGene Inc (NASDAQ:TROV) was released by: Prnewswire.com and their article: “Trovagene Schedules Release of Third Quarter 2016 Financial Results and …” with publication date: September 26, 2016.
TROV Company Profile
Trovagene, Inc. (TrovaGene), incorporated on September 21, 2009, is a molecular diagnostic company. The Firm focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. The Company’s primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. The Firm has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.